NeoPharm CO. LTD (092730) — Cash Flow-to-Debt Ratio
NeoPharm CO. LTD (092730) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of ₩5.88 Billion could theoretically repay 0% of its total liabilities (₩18.97 Billion) in one year. See financial agility of NeoPharm CO. LTD to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NeoPharm CO. LTD Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for NeoPharm CO. LTD across 11 annual periods. For the full cash flow conversion analysis, see NeoPharm CO. LTD (092730) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year debt coverage analysis for NeoPharm CO. LTD. Check 092730 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.20x | ₩18.63 Billion | ₩15.56 Billion | ▼ -10.2% |
| 2023 | 1.33x | ₩23.26 Billion | ₩17.43 Billion | ▼ -3.5% |
| 2022 | 1.38x | ₩18.16 Billion | ₩13.14 Billion | ▼ -16.5% |
| 2021 | 1.65x | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.9% |
| 2020 | 1.12x | ₩17.07 Billion | ₩15.26 Billion | ▼ -0.8% |
| 2019 | 1.13x | ₩19.22 Billion | ₩17.05 Billion | ▼ -4.9% |
| 2018 | 1.19x | ₩16.18 Billion | ₩13.64 Billion | ▲ +1.5% |
| 2017 | 1.17x | ₩10.65 Billion | ₩9.11 Billion | ▲ +1.3% |
| 2016 | 1.15x | ₩9.16 Billion | ₩7.94 Billion | ▲ +47.4% |
| 2015 | 0.78x | ₩6.09 Billion | ₩7.79 Billion | ▲ +485.1% |
| 2012 | 0.13x | ₩564.34 Million | ₩4.22 Billion | — |